Relay Therapeutics, Inc. Common Stock (RLAY) Stock
NASDAQ · RLAY
18.19
Fundamentals
Market cap
$4.13B
Price / Earnings ratio
-14.4x
Price / Sales ratio
398.9x
Price / Book ratio
4.6x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Relay Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees202
CEODr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
IPO DateJul 16, 2020
HeadquartersCambridge, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, President & Director | 1974 |
| Dr. Mark Murcko Ph.D. | Founder & Independent Director | 1960 |
| Mr. Thomas Catinazzo | Chief Financial Officer | 1976 |
| Mr. Peter Rahmer | Chief Corporate Development Officer | 1982 |
| Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research & Development | 1972 |
| Ms. Dorothee Kern Ph.D. | Founder | — |
| Dr. David Elliot Shaw Ph.D. | Founder | 1951 |
| Dr. Matthew P. Jacobson Ph.D. | Founder | — |
| Mr. Jim Watters Ph.D. | Chief Scientific Officer | — |
| Ms. Soo-Yeun Lim J.D. | Senior VP & General Counsel | — |
Fundamentals
Valuation
Market cap$4.13B
Price-to-sales ratio398.90
Price-to-book value4.64
Price-earnings ratio-14.40
Return on Equity-44.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.56
Income Statement
Average volume3,369,704
EBITDA$-269.85M
1 year high (52w)$21.27
1 year low (52w)$4.32
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



